WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H461164
CAS#: 851536-75-9
Description: Umirolimus is a sirolimus derivative from a biodegradable polylactic acid polymer; it possesses enhanced anti-inflammatory and antiproliferative activity with an improved pharmacokinetic profile.
Hodoodo Cat#: H461164
Name: Umirolimus
CAS#: 851536-75-9
Chemical Formula: C55H87NO14
Exact Mass: 985.61
Molecular Weight: 986.290
Elemental Analysis: C, 66.98; H, 8.89; N, 1.42; O, 22.71
Synonym: Umirolimus; TRM 986; TRM-986; TRM986; Biolimus A9; Biolimus-A9; BiolimusA9
IUPAC/Chemical Name: A name could not be generated for this structure.
InChi Key: YYSFXUWWPNHNAZ-PKJQJFMNSA-N
InChi Code: InChI=1S/C55H87NO14/c1-12-67-26-27-68-45-24-22-41(31-48(45)65-10)30-37(5)47-33-44(57)36(4)29-39(7)50(59)51(66-11)49(58)38(6)28-34(2)18-14-13-15-19-35(3)46(64-9)32-42-23-21-40(8)55(63,70-42)52(60)53(61)56-25-17-16-20-43(56)54(62)69-47/h13-15,18-19,29,34,36-38,40-43,45-48,50-51,59,63H,12,16-17,20-28,30-33H2,1-11H3/b15-13+,18-14+,35-19+,39-29+/t34-,36-,37-,38-,40-,41+,42+,43+,45-,46+,47+,48-,50-,51+,55-/m1/s1
SMILES Code: CCOCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@H]([C@@H]2CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@@H](OC)C[C@@H]3CC[C@H]([C@@](O3)(C(C(N4CCCC[C@H]4C(O2)=O)=O)=O)O)C)\C)C)C)=O)OC)O)\C)C)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 986.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14. PubMed PMID: 26466021.
2: Campos CM, Christiansen EH, Stone GW, Serruys PW. The EXCEL and NOBLE trials: similarities, contrasts and future perspectives for left main revascularisation. EuroIntervention. 2015;11 Suppl V:V115-9. doi: 10.4244/EIJV11SVA26. PubMed PMID: 25983143.
3: Lee JM, Cho DK, Hahn JY, Song YB, Park TK, Oh JH, Lee JB, Doh JH, Kim SH, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Am Heart J. 2016 Dec;182:1-8. doi: 10.1016/j.ahj.2016.07.022. Epub 2016 Aug 26. PubMed PMID: 27914488.
4: Buysschaert I, Verheye S. The Axxess stent. EuroIntervention. 2015;11 Suppl V:V143-4. doi: 10.4244/EIJV11SVA32. PubMed PMID: 25983150.
5: Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial. Circ Cardiovasc Interv. 2015 Oct;8(10). pii: e002817. doi: 10.1161/CIRCINTERVENTIONS.115.002817. PubMed PMID: 26446596.
6: Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Jüni P, Garcia-Garcia HM, van Es GA, Serruys PW. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention. 2016 Nov 20;12(10):1239-1245. doi: 10.4244/EIJY15M11_07. PubMed PMID: 26606735.
7: Webster MW, Ormiston JA. Drug-eluting stents--SORTed. Lancet. 2015 Apr 18;385(9977):1487-9. doi: 10.1016/S0140-6736(14)62009-2. Epub 2015 Jan 16. PubMed PMID: 25601787.
8: Tanaka K, Sata M. Visualization of the human coronary vasa vasorum in vivo. Circ J. 2015;79(6):1211-2. doi: 10.1253/circj.CJ-15-0356. Epub 2015 Apr 15. PubMed PMID: 25877739.
9: Abizaid A, Costa JR Jr, Gibson CM. Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes? J Am Coll Cardiol. 2015 Mar 3;65(8):802-804. doi: 10.1016/j.jacc.2014.12.016. PubMed PMID: 25720623.
10: Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017. PubMed PMID: 25720622.
11: Kim DR, Woo JS, Hwang SJ, Kim HS, Park CB, Cho JM, Kim CJ, Jeong MH, Kim W; Other Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Comparison of Biolimus- and Everolimus-eluting stents in terms of clinical outcomes in patients with acute myocardial infarction: Results from the Korea Working Group on Myocardial Infarction (KorMI) Registry. Int J Cardiol. 2015 Oct 1;196:50-2. doi: 10.1016/j.ijcard.2015.05.158. Epub 2015 May 30. PubMed PMID: 26080279.
12: Stabile E, Salemme L, Ferrone M, Arcari A, Cioppa A, Popusoi G, Pucciarelli A, Trimarco B, Esposito G, Tesorio T. Abluminal biodegradable polymer-based Biolimus A9-eluting stent for the treatment of infrapopliteal arteries in critical limb ischemia: Long-term follow-up. Int J Cardiol. 2016 Jan 1;202:98-9. doi: 10.1016/j.ijcard.2015.08.178. Epub 2015 Aug 28. PubMed PMID: 26386933.
13: Costa RA, Abizaid A, Mehran R, Schofer J, Schuler GC, Hauptmann KE, Magalhães MA, Parise H, Grube E; BioFreedom FIM Clinical Trial Investigators. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovasc Interv. 2016 Jan 11;9(1):51-64. doi: 10.1016/j.jcin.2015.09.008. PubMed PMID: 26762911.
14: Kallinikou Z, Arroyo D, Togni M, Lehman S, Corpataux N, Cook M, Müller O, Baeriswyl G, Stauffer JC, Goy JJ, Puricel SG, Cook S. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial. Swiss Med Wkly. 2016 Jan 14;146:w14274. doi: 10.4414/smw.2016.14274. eCollection 2016. PubMed PMID: 26766027.
15: Räber L, Kelbæk H, Taniwaki M, Ostojic M, Heg D, Baumbach A, von Birgelen C, Roffi M, Tüller D, Engstrøm T, Moschovitis A, Pedrazzini G, Wenaweser P, Kornowski R, Weber K, Lüscher TF, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv. 2014 Jun;7(3):355-64. doi: 10.1161/CIRCINTERVENTIONS.113.001440. Epub 2014 May 20. PubMed PMID: 24847017.
16: Goldberg A, Zdorovyak A, Rosenfeld I, Nordkin I. Early development of coronary artery aneurysms after implantation of biolimus-eluting stent with biodegradable polymer. Int J Cardiol. 2015 Apr 1;184:487-8. doi: 10.1016/j.ijcard.2015.02.082. Epub 2015 Feb 25. PubMed PMID: 25756573.
17: Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, Garg S, de Vries T, Garcia-Garcia HM, Onuma Y, de Winter RJ, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Meier B, Jüni P, Yazdani A, Copt S, Windecker S, Serruys PW. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2016 Jun;87(7):E248-60. doi: 10.1002/ccd.26344. Epub 2015 Dec 9. PubMed PMID: 26649651.
18: Ghione M, Wykrzykowska JJ, Windecker S, Serruys PW, Buszman P, Linke A, Sohn HY, Corti R, Antoni D, Wijns W, Estevez-Loureiro R, Morice MC, Van Es GA, van Geuns RJ, Juni P, Eerdmans P, De Vries T, Konik S, Di Mario C. Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial. Cardiol J. 2016;23(6):626-636. doi: 10.5603/CJ.a2016.0071. Epub 2016 Sep 26. PubMed PMID: 27665852.
19: Verheye S, Buysschaert I, Grube E. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system. EuroIntervention. 2015 Dec;11(8):860-7. doi: 10.4244/EIJV11I8A176. PubMed PMID: 26696454.
20: Nakao F. Instant Stent-Accentuated 3-Dimensional Optical Coherence Tomography of Struts Pulled Up by Pulling Stuck Wire and Folded by Kissing Balloon Dilation. JACC Cardiovasc Interv. 2015 Jul;8(8):e125-e126. doi: 10.1016/j.jcin.2015.01.038. Epub 2015 Jun 24. PubMed PMID: 26117467.
